As the need for cancer-related treatments increases, it is becoming increasingly important to partner with an Oncology CRO. A successful partnership will require seasoned staff across all functions with proven track records in Oncology CRO. Several companies have emerged as Leading Oncology CRO Companies. These companies are Vial, PharPoint Research, and Precision for Medicine.
Vial Oncology CRO
Vial is an oncology CRO with in the long run of working with biotechnology sponsors. The company has recently merged with Catalyst Clinical Research, creating a comprehensive Oncology CRO Solution. The two companies will have separate management teams, but the combined company will continue to provide oncology clinical development services.
Vial Oncology CRO has extensive experience working with premier oncology sites in the US. Let’s oncology staff has expertise with protocol design, site selection, and project management. Additionally, they’re experienced in regulatory submissions for the US market. The firm also provides services such as electronic data capture and statistical consulting.
Sue McLaughlin has more than 20 years of experience in clinical development research. Sue McLaughlin began her career at Pfizer, where she worked in various clinical operations roles. She went on to join Vial Oncology CRO, a start-up CRO, and served in a variety of senior positions in the Business and Clinical Operations departments. She led the team’s relationship management efforts.
Oncotech Therapeutics focuses on providing early-phase clinical development services in the oncology space. With expertise in novel therapies, the team at this Oncology CRO understands the unique needs of biotechnology companies. The company also provides expert, regulatory consulting, and support for its clients, enabling them to achieve their clinical development goals.
Vial Oncology CRO works with an advisory board of industry leaders to provide guidance and support to the company. The board provides insight, strategy, and expertise.
Novotech
Novotech is an Oncology CRO with a growing client base. Its extensive global network in addition offices throughout Asia-Pacific. It has deep industry expertise and strong relationships with sites, enabling it to provide a streamlined clinical trial process. It is also backed by its reputation for high-quality studies.
Novotech works with biotechnology companies to conduct Phase II studies. It recently completed a phase I study for a South Korean biotechnology company. The company was looking to progress to the next phase, and needed an Oncology CRO to help. Novotech’s oncology CRO services in addition reviewing the initial phase II protocol, providing medical writing services, and ensuring the primary endpoints and data collected complied with South Korean regulatory requirements. The team also managed site initiations and established strong relationships with the sponsor and PI.
Novotech is now in the midst of a Phase 1b/2 study for HER-Vaxx, an immunotherapy treatment for HER-2-positive gastric cancer. The company plans to recruit patients who have been diagnosed with the disease, and to enroll them in an open-label, dose-escalation study. The Phase 1b study will also assess the safety of the drug and help determine the right dose. The Phase 2 study will evaluate the effectiveness of HER-Vaxx in combination with standard-of-care.
Read also: CTMS – Clinical Trial Management System
PharPoint Research
PharPoint Research is an award-winning CRO based in the United States. The firm works with innovative pharmaceutical, biotechnology, and medical device companies to deliver high-quality services across the clinical development life cycle. The company specializes in biostatistics, statistical programming, data management, and clinical operations. It also provides strategic clinical trial consulting services. Read on to learn more about the services offered by PharPoint.
PharPoint Research has recently expanded its Durham and Wilmington offices to accommodate the accelerated growth of clinical research in North Carolina. This expansion will allow the firm to better serve clients and increase its presence in the pharmaceutical industry. The company currently staffs over 100 people at these offices. This growth in North Carolina has led to the company securing several new contracts.
PharPoint is also a great choice for those looking for a CRO that specializes in the field of oncology. Its experts have the industry experience to guide studies through any bumps in the road. Its leadership team members average more than 25 years of experience in the field of clinical research. They have seen nearly everything that can go wrong in a clinical trial and have developed proactive measures to put them back on track.
PharPoint has an oncology CRO that has more than two decades of experience in this field. They have conducted over 100 oncology clinical trials, and are a trusted source for U.S. drug developers when their programs do not meet deadlines. Its clinical trial sites typically rank among the top en rollers in oncology studies worldwide.
Precision for Medicine Oncology CRO
Precision for Medicine, a leading oncology CRO, specializes in advancing the research pipeline of cancer therapies. The company combines a deep scientific expertise with innovative clinical trial designs to support the development of personalized medicines. It also provides industry-leading operational expertise and advanced biomarker solutions.
Precision medicine aims to develop therapies based on individual differences and is changing the way cancer treatments are delivered. Pioneers of precision medicine are small biotech and specialty pharmaceutical companies that sometimes are comprised of just one molecule or a group of scientists. By identifying unique patient characteristics and leveraging a precision medicine approach, they can help translate brilliant ideas into practical products.
Precision for Medicine is rapidly expanding its European operations. This expansion will help address a critical problem for developers of cancer treatments: patient recruitment. It plans to prioritize adding European laboratories, and anticipates negotiating future acquisitions. For now, it has established a presence in five European countries.
Its leadership team should be comprised of key stakeholders from the medical community and other relevant practices. This group should provide ongoing education and support to its precision medicine partners. The precision-medicine field is constantly evolving, so it’s important for CROs to stay current. This way, they can stay one step ahead of the competition and deliver innovative products to the marketplace.
The process of analyzing clinical trial data is particularly critical for precision medicine clinical trials. It’s important to ensure that all study data is collected and maintained in an organized manner. Using an electronic data capture tool will help future queries and quality checks.
Celerion
The Celerion Oncology CRO has a proven track record of supporting multi-site and multi-country oncology drug development studies. They offer clients access to top investigators, highly skilled project teams, and specialized network of laboratories. Their comprehensive portfolio in addition research in immuno-oncology, pharmacokinetics, and safety.
Celerion Oncology CRO has over 40 years of experience and has strategically located facilities in North America, Europe, and Asia. With more than 750 beds dedicated to Phase I and Phase II clinical research, Celerion is a premier CRO in the field. Their integrated capabilities and bio analytical capabilities enable them to manage complex study designs and deliver high quality accelerated results.
Its research staff in addition over 40 experienced scientists. They have 5,000 protocols under their belts and produce over 200 clinical study reports each year. In addition, the CRO is a member of the Clinical Data Interchange Standards Consortium (CDISC) and supports SDTM and ADaM compliant packages. They also participate in driving initiatives to implement future data standards.
The Celerion Clinical Trials Center, located in South Korea, has a focus on translational medicine. They’re working with three other clinical-trial centers in South Korea and have built relationships with them. Celerion is also addressing another key point the need for multi-site early studies for patients who require confinement. Contract Research Organization office will be led by John Horkulak, who will oversee the company’s operations in the region.
